Santoro, MatteoMaetzler, WalterStathakos, PetrosMartin, Heather L.Hobert, Markus A.Rattray, Tim W.Gasser, ThomasForrester, John V.Berg, DanielaTracey, Kevin J.Riedel, GernotTeismann, Peter2016-03-292016-03-292016-07Santoro, M, Maetzler, W, Stathakos, P, Martin, H L, Hobert, M A, Rattray, T W, Gasser, T, Forrester, J V, Berg, D, Tracey, K J, Riedel, G & Teismann, P 2016, 'In-vivo evidence that high mobility group box 1 exerts deleterious effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model and Parkinson's disease which can be attenuated by glycyrrhizin', Neurobiology of Disease, vol. 91, pp. 59-68. https://doi.org/10.1016/j.nbd.2016.02.0180969-9961http://hdl.handle.net/2164/5783Acknowledgements Samples were obtained from the Neuro Biobank of the University of Tuebingen, Germany (http://www.hih-tuebingen.de/nd/biobank/for-researchers/). This biobank is supported by the Hertie Institute and the DZNE. We are grateful to the staff of the Medical Research Facility for their help with the animal care. We thank Dr. Kinnari Sathe for her help with the experiments. We thank Claire A. Walker for assisting with western blot analysis. This study was supported by: Tenovus Scotland, Parkinson's Disease Foundation, Royal Society 2006/R1, NHS Endowment 14-42, and Wellcome Trust WT080782MF.102990444engSDG 3 - Good Health and Well-beingParkinson's diseaseMPTPHigh-mobility group box 1receptor for advanced glycation endproductsRC0321 Neuroscience. Biological psychiatry. NeuropsychiatryWellcome TrustWT080782MFRC0321Journal article10.1016/j.nbd.2016.02.01891